Effectiveness and safety of bedaquiline-based, modified all-oral 9–11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam-Reference-Cited by-同舟云学术

Effectiveness and safety of bedaquiline-based, modified all-oral 9–11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam

Published:2023-01 Issue: Volume:126 Page:148-154
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Nguyen Thi Mai Phuong^ORCID,Le Thi Hai Minh,Merle Corinne Simone Collette^ORCID,Pedrazzoli Debora^ORCID,Nguyen Nhat Linh,Decroo Tom,Nguyen Binh Hoa^ORCID,Hoang Thi Thanh Thuy,Nguyen Viet Nhung^ORCID

Funder

The Global Fund to Fight AIDS Tuberculosis and Malaria

World Health Organization

World Health Organization TDR

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference30 articles.

1. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients;Aung;Int J Tuberc Lung Dis,2014

2. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019–2020;Avaliani;Monaldi Arch Chest Dis,2021

3. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report;Borisov;Eur Respir J,2019

4. Treatment of highly drug-resistant pulmonary tuberculosis;Conradie;N Engl J Med,2020

5. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis;Court;Int J Infect Dis,2021

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of bedaquiline containing all oral longer regimens in treating multidrug/rifampicin resistant tuberculosis in Pakistan;Journal of Infection and Public Health;2024-09

2. Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan;Clinical Infectious Diseases;2024-06-04

3. Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis;The Lancet Infectious Diseases;2024-06

4. Systematic review of efficacy and safety of shorter regimens for drug-resistant tuberculosis (DR-TB) in children;Clinical Epidemiology and Global Health;2024-05

5. Evaluation of a Modified Short all oral Treatment Regimen for Rifampicin-Multidrug Resistant Tuberculosis in Dominican Republic;2024-04-29